[1] AKUTA N,SUZUKI F,SUZUKI Y,et al. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B：an 8-year follow-up study[J]. J Med Virol. 2005,75（4）:491-498.
[2] 宋闽宁,骆梅兰,闵峰。血浆置换对重型肝炎并发感染的影响[J]. 中国危重病急救医学,2003,15（2）120-121.
[3] ONAS MM,LITITIS NR GRDNER SD et al. Long-term lamivudine treatment of children with chronic hepatitis B：durability of therapeutic responses and safety[J]. J Viral Hepat. 2008,15（1）：20-27.
[4] 中华医学会感染病学分会肝衰竭与人工肝学组和肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J]. 实用肝脏病杂志,2006,9（6）：321-324.
[5] DElLIC D,NESIC Z,PROSTRAN M. Treatment of subacute hepatitis B with lamivudine：a pilot study in Serbia[J]. Vojnosanit Pregl. 2009,66（3）:199-202.
[6] ROSSOS A,KOILAKOU S,KALAfAtTAS I. Lamivudine treatment for acute severe hepatitis B：report of a case and review of the literature[J]. Acta Gastroenterol Belg. 2008,71（1）:30-32.
[7] TILLMANN HL,HADEM J,LEIFELD L,et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B,a multicenter experience[J]. J Viral Hepat,2006,13 （4）：256-263.
[8] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南[J]. 实用肝脏病杂志,2006,9（1）：8-18.
[9] TSUBOTA A,ARASE Y,SUZUKI Y,et al. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B[J]. J Gastroenterol Hepatol,2005,20（3）：426-432.
[10] CHEN CJ,YANgG HI,SU J,et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA. 2006,295（1）：65-73. |
